XIENCE V Adverse Events: FDA MAUDE Data
ABBOTT VASCULAR INC. · Coronary Drug-Eluting Stent · First cleared Aug 2011 · 30 device variants grouped
Total Reports
963
Reports (30d)
9
Active Signals
0
Open Recalls
0
What the reports describe · Claripulse analysis
Most commonly reported problems
DAPT Duration Impact on Bleeding Risk
month, dapt, patients, bleeding, group
7
reports
Post-Market Clinical Evaluation Findings
evaluation report, polymer, clinical follow, market clinical, post market
4
reports
Proximal Edge Dissection During Implant
delay procedure, treat, provided procedure, procedure additional, significant delay
4
reports
Residual Stenosis Post-Stent Treatment
residual stenosis, timi flow, synergy, aspirin, residual
2
reports
Balloon Retrieval Difficulty and Shaft Break
synergy, delivery, selected, shaft, synergy drug
1
reports
Cardiac Arrest Post-Procedure
death, synergy, cardiac, ivus, patients
1
reports
Problem groupings are generated by Claripulse from report narrative text. They summarize what reporters wrote, not adjudicated root cause.
Evidence
Related research
Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy
Andreas Mitsis, et al. · Expert Review of Medical Devices · 2020
Four-Year Outcomes of Multivessel Percutaneous Coronary Intervention With Xience V Everolimus-Eluting Stents.
Lee MS, et al. · The Journal of invasive cardiology · 2019
Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry
You‐Jeong Ki, et al. · Journal of Interventional Cardiology · 2020
A clinical evaluation of the XIENCE V everolimus eluting stent in the treatment of patients with coronary artery disease: Result from Thailand Registry - XIENCE V performance evaluation (THRIVE study).
Kiatchoosakun S, et al. · Indian heart journal · 2016
Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study
Waiel A. Abusnina, et al. · Catheterization and Cardiovascular Interventions · 2024
Citations indexed from PubMed.
Keep exploring
Related devices in Coronary
Perclose ProGlide
ABBOTT VASCULAR INC. · 24,665 reports
Perclose ProStyle
ABBOTT VASCULAR INC. · 19,648 reports
PERCLOSE
ABBOTT VASCULAR INC. · 10,164 reports
SYNERGY
BOSTON SCIENTIFIC CORPORATION · 7,061 reports
Angio-Seal
TERUMO MEDICAL CORPORATION · 6,783 reports
Resolute Onyx
MEDTRONIC, INC. · 4,510 reports
Want automated safety signal detection?
Claripulse monitors these devices weekly and detects anomalies using 6 statistical methods — spike, trend, changepoint, peer-outlier, and more.
Get Early AccessUnderstanding this data